Bone Mass Accrual in Children With Autism Spectrum Disorder

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03162445

Enrollment

Registered

2017-05-22

Start date

2010-01-11

Completion date

2016-01-31

Last updated

2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder, Bone Diseases, Developmental

Keywords

bone mineral density, Autism Spectrum Disorder, Autism

Brief summary

This is a observational study to investigate the degree to which bone mineral density is impaired in boys with autism compared with typically developing controls.

Detailed description

Studies have shown that bone cortical thickness is decreased in children with autism and other developmental disabilities. However it is not known whether bone mineral density (BMD) of these children is lower; neither is it known whether there is any correlation between BMD and the child's diet. The overall goal of this study is to improve the long term health of children and adolescents with autism spectrum disorder; more specifically the investigators aim to develop a pilot study to investigate the degree to which BMD is impaired in boys with autism and to explore specific additional risk factors. In addition, the aim is to investigate the degree to which BMD is impaired in boys with Autism Spectrum Disorder (ASD) and to explore specific contributing risk factors including nutritional analysis.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

8 Years to 17 Years

Healthy volunteers

Yes

Inclusion criteria

* Boys 8-17 years chronological age * BMI between the 3rd and 97th percentiles * Meets DSM-IV criteria for Autism Spectrum Disorder (ASD group) * Scores \<15 on the Social Communication Questionnaire (control group)

Exclusion criteria

* Use of medications directly affecting bone metabolism including estrogen/ progesterone preparations and glucocorticoids except local application of glucocorticoid * Use of anticonvulsants which affect bone density including diphenylhydantoin, phenobarbital, topiramate carbamazepine and valproic acid and also use of lithium * Children with diseases known to affect bone mineral density including Crohn's disease, celiac, thyroid and renal * Children who will not tolerate lying still for 30 seconds

Design outcomes

Primary

Measure	Time frame	Description
Bone Mineral Density	Bone mineral density will be assessed within one month of enrolling in the study.	using dual energy x-ray absorptiometry (DXA) (Hologic Discovery A, Software Version: APEX 4.0.2, Bedford, MA USA) at the total hip, femoral neck, lumbar spine (L1-4), whole body and whole body less head bone mineral density.

Outcome results